logo

For the Inventor, By the Inventor

Wayne, NJ, United States of America

Linda L Chang

This inventor holds 22 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in Cell Adhesion Inhibitors. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Merck Frosst Canada, Inc.. Active years: 1993-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Linda L Chang. Retrieved from https://idiyas.com/inventor/linda-l-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 

% Patents Active = 72.7

 

Average Co-Inventor Count = 3.7

ph-index = 10

Forward Citations = 299(Granted Patents)


Company Filing History:

goldMedal20 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal2 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal1 out of 212 
 
Merck Frosst Canada, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1993-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Cell Adhesion Inhibitors
Substituted Amides
Triazole Derivatives
Glucagon Antagonists
Amino Acid Derivatives
Heterocycle Amides
Endothelin Antagonists
Pyridine Compounds
Aza-Bicyclic Derivatives
Pyrrole Derivatives
Diazepine Sulfonamides
Cyclic Compounds
22 patents (USPTO):Explore Patents
1. 8153626 - Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators (2012-04-10),
2. 7816534 - Substituted amides (2010-10-19),
3. 7629467 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use (2009-12-08),
4. 7550489 - Substituted pyridyoxy amides (2009-06-23),
5. 6972295 - Substituted amides (2005-12-06),
6. 6943180 - Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors (2005-09-13),
7. 6855708 - N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors (2005-02-15),
8. 6559174 - N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors (2003-05-06),
9. 6420418 - Heterocycle amides as cell adhesion inhibitors (2002-07-16),
10. 6271252 - Cyclic amino acid derivatives as cell adhesion inhibitors (2001-08-07),
11. 6090841 - Substituted pyrrole derivatives as cell adhesion inhibitors (2000-07-18),
12. 5955480 - Triaryl substituted imidazoles, compositions containing such compounds (1999-09-21),
13. 5880139 - Triaryl substituted imidazoles as glucagon antagonists (1999-03-09),
14. 5776954 - Substituted pyridyl pyrroles, compositions containing such compounds and (1998-07-07),
15. 5559135 - Endothelin antagonists bearing pyridyl amides (1996-09-24),

Title: Linda L. Chang: A Pioneering Inventor in Pharmaceutical Innovations

Introduction: Linda L. Chang, based in Wayne, NJ, is a distinguished inventor with an impressive portfolio of 22 patents. Her work focuses on innovative compounds that address various medical conditions, demonstrating her commitment to advancing pharmaceutical science and improving patient outcomes.

Latest Patents: Chang's latest contributions to the field include notable patents for novel compounds such as substituted diazepine sulfonamides, which serve as modulators for the human bombesin receptor subtype-3 (BRS-3). These compounds are particularly useful for treating and preventing disorders responsive to BRS-3 modulation, including obesity and diabetes. Additionally, she has developed substituted amides that act as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor. These innovative compounds have the potential to treat a wide array of medical issues, from psychosis and cognitive disorders to weight management and substance abuse disorders.

Career Highlights: Throughout her career, Linda L. Chang has made significant strides in the pharmaceutical industry while working at renowned companies including Merck & Company, Inc. and Merck Sharp & Dohme Corporation. Her dedication to research and development has led to impactful advancements in medications that address severe health challenges.

Collaborations: Chang has collaborated with esteemed colleagues, such as William K. Hagmann and Wallace T. Ashton. Their collective expertise and innovative ideas have undoubtedly contributed to the success and effectiveness of the patented compounds developed by Chang.

Conclusion: Linda L. Chang stands as a testament to the power of innovation in the pharmaceutical sector. With her extensive background and groundbreaking patents, she continues to make a profound impact on the treatment of various diseases. Her work reflects the importance of perseverance and creativity in the quest for medical advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…